CN114224907A - 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 - Google Patents

包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 Download PDF

Info

Publication number
CN114224907A
CN114224907A CN202111383325.9A CN202111383325A CN114224907A CN 114224907 A CN114224907 A CN 114224907A CN 202111383325 A CN202111383325 A CN 202111383325A CN 114224907 A CN114224907 A CN 114224907A
Authority
CN
China
Prior art keywords
various embodiments
substituted
unsubstituted
cpg
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111383325.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·T·科尔蒂莱夫斯基
P·M·希维德尔斯基
D·F·莫雷拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of CN114224907A publication Critical patent/CN114224907A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202111383325.9A 2015-07-02 2016-06-30 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 Pending CN114224907A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562187878P 2015-07-02 2015-07-02
US62/187,878 2015-07-02
US201562264026P 2015-12-07 2015-12-07
US62/264,026 2015-12-07
CN201680047408.1A CN107980001B (zh) 2015-07-02 2016-06-30 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
PCT/US2016/040361 WO2017004357A1 (en) 2015-07-02 2016-06-30 Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680047408.1A Division CN107980001B (zh) 2015-07-02 2016-06-30 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Publications (1)

Publication Number Publication Date
CN114224907A true CN114224907A (zh) 2022-03-25

Family

ID=57609287

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111383325.9A Pending CN114224907A (zh) 2015-07-02 2016-06-30 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
CN201680047408.1A Active CN107980001B (zh) 2015-07-02 2016-06-30 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680047408.1A Active CN107980001B (zh) 2015-07-02 2016-06-30 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Country Status (6)

Country Link
US (3) US10758624B2 (enExample)
EP (1) EP3316894A4 (enExample)
JP (2) JP7073109B2 (enExample)
CN (2) CN114224907A (enExample)
CA (1) CA2991052A1 (enExample)
WO (1) WO2017004357A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114908094A (zh) * 2022-05-31 2022-08-16 中山大学 一类反义寡核苷酸分子及其在制备治疗恶性肿瘤药物中的应用
CN118480552A (zh) * 2024-01-18 2024-08-13 成都先衍生物技术有限公司 一种靶向CEBPA基因表达的saRNA及其用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972986A1 (en) 2015-01-16 2016-07-21 City Of Hope Cell penetrating antibodies
US10912790B2 (en) 2015-04-22 2021-02-09 Mina Therapeutics Limited C/EBP alpha saRNA compositions and methods of use
CN114224907A (zh) * 2015-07-02 2022-03-25 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
SG11201906728TA (en) 2017-02-06 2019-08-27 Mpeg La Llc Multimeric oligonucleotides having decreased kidney clearance
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
WO2019006371A1 (en) * 2017-06-30 2019-01-03 City Of Hope COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY
AU2018330495A1 (en) 2017-09-08 2020-03-26 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
KR20200143428A (ko) * 2018-04-10 2020-12-23 락티젠 세러퓨틱스 P21 유전자 발현을 활성화하는 방법
WO2019241766A1 (en) * 2018-06-15 2019-12-19 City Of Hope Oligonucleotide-based proteolysis targeting chimera
CN109762042B (zh) * 2018-09-21 2022-04-08 河北艾克美冀生物科技有限公司 一种治疗癌症的药物、其合成方法和应用
JP2022523226A (ja) * 2019-03-04 2022-04-21 エムペグ エルエイ リミテッド ライアビリティ カンパニー 増強された生理活性を有する多量体オリゴヌクレオチド
EP4003423A4 (en) * 2019-07-26 2024-03-06 MiNA Therapeutics Limited Compositions and methods of using c/ebp alpha sarna
KR102433981B1 (ko) * 2020-12-15 2022-08-19 대구가톨릭대학교산학협력단 HIF-1α 및 STAT5 전사인자를 억제하는 합성 디코이 올리고핵산 및 이를 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 약학적 조성물
JP2024506042A (ja) * 2021-02-08 2024-02-08 ラクティゲン セラピューティクス 多価オリゴヌクレオチド薬剤およびその使用方法
US20250376689A1 (en) * 2021-08-31 2025-12-11 City Of Hope Oligonucleotides having 6-thio-2'-deoxyguanosine residues and uses thereof
WO2024077228A2 (en) * 2022-10-07 2024-04-11 City Of Hope Double-stranded oligonucleotides and methods of use
EP4627086A2 (en) * 2022-11-29 2025-10-08 Lonza Sales AG Methods of using extracellular vesicle-aso targeting stat6

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060046259A1 (en) * 2004-05-27 2006-03-02 The Gov. Of The U.S.A As Represented By The Secretary Of The Dept. Of Health & Human Services Differential expression of molecules associated with acute stroke
US20100210707A1 (en) * 2005-04-15 2010-08-19 Longcheng Li Small Activating RNA Molecules and Methods of Use
CN101848923A (zh) * 2007-05-01 2010-09-29 希望之城 通过双链rna特异性抑制基因表达的方法和组合物
US20140287987A1 (en) * 2007-01-26 2014-09-25 City Of Hope Methods and compositions for the treatment of cancer or other diseases
WO2015075557A2 (en) * 2013-11-22 2015-05-28 Mina Alpha Limited C/ebp alpha compositions and methods of use
CN107980001A (zh) * 2015-07-02 2018-05-01 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6867289B1 (en) * 1998-10-26 2005-03-15 Board Of Regents, The University Of Texas Systems Thio-modified aptamer synthetic methods and compositions
US6159694A (en) 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
AU2007345648A1 (en) 2007-01-26 2008-08-07 City Of Hope Methods and compositions for the treatment of cancer or other diseases
US20110250138A1 (en) * 2007-08-01 2011-10-13 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand
EP2370582B1 (en) * 2008-12-04 2017-05-10 CuRNA, Inc. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
WO2012128785A1 (en) 2011-03-22 2012-09-27 City Of Hope Methods and compositions for the treatment of cancer or other diseases
MY163004A (en) 2011-04-01 2017-07-31 Ionis Pharmaceuticals Inc Modulation of signal transducer and activator of transcription 3 (stat3) expression
WO2014047649A1 (en) * 2012-09-24 2014-03-27 The Regents Of The University Of California Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy
PL2920308T3 (pl) * 2012-10-31 2019-06-28 Ionis Pharmaceuticals, Inc. Leczenie nowotworu
MX2015013021A (es) * 2013-03-14 2016-07-14 Nat And Kapodistrian University Of Athens 5-bromo-indirrubinas.
WO2015077657A2 (en) 2013-11-22 2015-05-28 City Of Hope Stat3 inhibitors and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060046259A1 (en) * 2004-05-27 2006-03-02 The Gov. Of The U.S.A As Represented By The Secretary Of The Dept. Of Health & Human Services Differential expression of molecules associated with acute stroke
US20100210707A1 (en) * 2005-04-15 2010-08-19 Longcheng Li Small Activating RNA Molecules and Methods of Use
US20140287987A1 (en) * 2007-01-26 2014-09-25 City Of Hope Methods and compositions for the treatment of cancer or other diseases
CN101848923A (zh) * 2007-05-01 2010-09-29 希望之城 通过双链rna特异性抑制基因表达的方法和组合物
WO2015075557A2 (en) * 2013-11-22 2015-05-28 Mina Alpha Limited C/ebp alpha compositions and methods of use
CN107980001A (zh) * 2015-07-02 2018-05-01 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114908094A (zh) * 2022-05-31 2022-08-16 中山大学 一类反义寡核苷酸分子及其在制备治疗恶性肿瘤药物中的应用
CN114908094B (zh) * 2022-05-31 2024-03-12 中山大学 一类反义寡核苷酸分子及其在制备治疗恶性肿瘤药物中的应用
CN118480552A (zh) * 2024-01-18 2024-08-13 成都先衍生物技术有限公司 一种靶向CEBPA基因表达的saRNA及其用途

Also Published As

Publication number Publication date
US20210038733A1 (en) 2021-02-11
CN107980001B (zh) 2021-12-17
US20180185497A1 (en) 2018-07-05
US11464865B2 (en) 2022-10-11
US20220401563A1 (en) 2022-12-22
JP7459168B2 (ja) 2024-04-01
JP2018519831A (ja) 2018-07-26
JP2022116006A (ja) 2022-08-09
JP7073109B2 (ja) 2022-05-23
EP3316894A1 (en) 2018-05-09
CN107980001A (zh) 2018-05-01
CA2991052A1 (en) 2017-01-05
WO2017004357A1 (en) 2017-01-05
EP3316894A4 (en) 2019-06-19
US10758624B2 (en) 2020-09-01

Similar Documents

Publication Publication Date Title
CN107980001B (zh) 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
US12227745B2 (en) Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
CN113795280B (zh) 核酸、药物组合物与缀合物及制备方法和用途
EP3228326A1 (en) Nucleic acid linked to a trivalent glycoconjugate
CN115666659A (zh) 稳定性增加的修饰的寡核苷酸的合成
JP2022534069A (ja) 核酸、薬物組成物及び複合体並びに調製方法と使用
JP2024505035A (ja) 中枢神経系における遺伝子発現を阻害するための組成物および方法
EP3974533A1 (en) Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
CN118922542A (zh) Stat3靶向寡核苷酸与pd-l1抑制剂的组合
CN117015384A (zh) Rnai缀合物及其用途
CN107709561A (zh) 修饰的siRNA及含有该修饰的siRNA的药物组合物
CN120303403A (zh) Stat3靶向寡核苷酸及其用途
HK40057145B (zh) 核酸、药物组合物与缀合物及制备方法和用途
HK40057142B (zh) 核酸、药物组合物与缀合物及制备方法和用途
HK40056327B (zh) 核酸、药物组合物与缀合物及制备方法和用途
HK40056327A (zh) 核酸、药物组合物与缀合物及制备方法和用途
HK40053351B (zh) 核酸、药物组合物与缀合物及制备方法和用途
HK40051484B (zh) 核酸、药物组合物与缀合物及制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220325

WD01 Invention patent application deemed withdrawn after publication